CH505TF gp120 (produced from stably transfected cells)

· National Institute of Allergy and Infectious Diseases (NIAID)

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for CH505TF gp120 (produced from stably transfected cells), covering 2022-07-11 to 2022-07-11. Get the full timeline:

Most recent: Clinical Trial Update: A Clinical Trial in Healthy, HIV-1-Uninfected Adult Participants to Compare the Safety, Tolerability and Immunogenicity of CH505TF gp120 Produced From Stably Transfected Cells to CH505TF gp120 Produced From Transiently Transfected Cells [Phase 1]

See pricing